Chapter 3

Revenue Durability

Molina has no moat in the ordinary sense. Its customers are roughly forty state Medicaid agencies that put their business out to competitive bid on three-to-five-year cycles, and four states supply 54% of Medicaid premium [1]. What stands in for a moat is an operational engine that has retained reprocurements and won new states for a decade, feeding a market that grows structurally. The ten-year revenue question is answerable yes with reasonable confidence — but the near-term direction is down.

The customer is a bidding process, not a captive base

The reader's central question — can revenue be higher in year ten — turns first on how Molina's revenue is held. It is held by contract, not by captivity. States select managed-care plans "by using a formal bid process," and Molina's Medicaid contracts "typically have terms of three to five years," carry renewal options the state controls, and let either side "terminate the contract with or without cause." When a state rebids through a request-for-proposal, "if one of our health plans is not a successful responsive bidder to such RFPs, its contract may not be renewed" [2].

That is the opposite of a switching-cost business. There is no brand pricing power — in Medicaid the plan is "essentially [a] rate taker," paid a fixed per-member rate set by the state [3]. And the revenue rests on a thin base of contracts: Molina operates "as a direct contractor with the states," and "the loss of any one of those contracts could have a material adverse effect" [4]. Whatever durability exists has to come from Molina winning the bids, not from customers being unable to leave.

What the track record shows instead

The evidence that Molina wins the bids is a decade long. Since it began its growth strategy in 2019, the company reports "a highly successful track-record of winning state RFPs," retaining reprocurements across the great majority of its footprint [5]. New-state procurements added roughly $7B of premium realized between 2019 and 2024, and bolt-on acquisitions added about $9B of premium over the same window [6]. The most recent proof point is Florida's Children's Medical Services program — a roughly $6 billion award management calls "one of the largest awards in Managed Medicaid history," carrying an estimated $2.00 of EPS at full implementation [7].

The long revenue arc is the cleanest test of durability, and it passes. Revenue roughly tripled over the last five years and is about 2.5x its level a decade ago — and it did so through a genuine crisis. In 2017 Molina posted a net loss of about $512 million; it restructured, and revenue and profit recovered and then compounded.

Source: derived from reported financials, FY2016–FY2025 (company filings, as reported); FY2017 reflects a net loss of about $512M.

The point is not that the past guarantees the future, but that the win-and-retain engine has been observed working across many procurement cycles and one near-death year. For a business with no captive customers, a demonstrated ability to keep winning is the durable asset — an operational and scale advantage, not a brand.

The concentration that a rebid can expose

The same thin-contract structure that makes the win rate load-bearing also makes concentration a real risk. Molina's top four health plans — California, New York, Texas, and Washington — carried aggregate Medicaid premium of $17.3 billion in 2025, about 54% of total Medicaid premium; Medicaid itself is 75% of consolidated premium [8]. Measured against total premium, California, Texas, and Washington were each at or above 10% [9].

Source: FY2025 Form 10-K, Item 1A [10]; FY2026 guidance per company disclosure [11].

Each of these contracts comes up for rebid on its own clock. California's Medi-Cal contracts recommenced in January 2024, and Texas STAR+PLUS was retained and expanded on a new contract from September 2024 [12]. Washington — one of the four — is the near-term watch item: the state is expected to re-procure its Medicaid business with an RFP no earlier than the fourth quarter of 2026 and a new contract effective January 1, 2028 [13]. The base case, on the track record, is retention; the tail risk is that a single lost rebid removes a tenth of the premium book at once.

Sources: FY2025 Form 10-K, Item 1 [14] and Note 2 [15]; Washington timing per FY2025 Form 10-K [16]. Blank cells not separately disclosed.

The policy overhang, and why 2026 goes backward

Winning bids protects Molina's share of the Medicaid pie; it does not protect the size of the pie. That is set in Washington and the state capitals, and for the first time in years it is contracting. Two federal changes bear directly on the ten-year top line.

First, the One Big Beautiful Bill Act, enacted July 2025, adds Medicaid work requirements and more frequent eligibility reverifications for the expansion population, phasing in from 2027. Management estimates the ultimate hit at 15% to 20% of its 1.3 million expansion members, arguing many will keep coverage through exclusions or because they already work; harder to size are the indirect effects of federal funding cuts to directed payments and provider taxes, which could push states to trim eligibility or benefits over 2027–2029 [17]. Second, the enhanced ACA subsidies that inflated Marketplace enrollment expired at the end of 2025, and a new program-integrity rule tightens eligibility from 2026 [18]. Molina had already chosen to keep Marketplace to about 10% of its book and let it shrink [19].

The result is a rare reversal. Molina guides FY2026 premium revenue to about $42 billion [20] — below the $43.1 billion of premium earned in 2025, with Medicaid enrollment expected roughly flat and a modest footprint contraction offset by the new Florida Kids contract from late 2026 [21]. The speed of that mark-down is its own data point: as recently as July 2025 management still targeted about $46 billion of 2026 premium and at least $52 billion for 2027 [22]. Seven months later the 2026 number was roughly $4 billion lower. A book of business this exposed to annual rate resets and federal policy does not compound in a straight line.

Sources: FY2024/FY2025 premium per reported results; FY2026 guidance [23]; 2029 target of $64B premium per 2026 Investor Day [24].

Underwriting year ten

On the reader's specific bar — 90% confidence that revenue is higher in year ten than today — the evidence supports a yes, with the reasons stated plainly. The addressable market grows structurally: Medicaid and Medicare spending rises with an aging population and medical inflation regardless of Molina's share, and states keep outsourcing to managed care for budget predictability [25]. Molina has shown, across a decade and dozens of procurements, that it can hold and grow its slice through RFP wins and M&A [26]. Management's own 2029 target — roughly $64 billion of premium, about 50% above the 2026 trough — quantifies its confidence [27].

The strongest fact against the confident read is that the pie can shrink faster than share can be won: an unusually adverse combination of OBBBA eligibility losses, state funding cuts, and a lost top-four rebid could hold revenue flat or lower for years, and 2026's reversal shows the machine can run backward [28]. What would change the read is concrete and near-term: a lost Washington reprocurement in 2026–2028, or evidence that the indirect OBBBA funding cuts are prompting states to cut managed-care eligibility rather than backfill with their own revenue [29]. The base case is that revenue is materially higher in a decade; the case is more exposed to policy than to competition, and the durability is in the franchise's proven ability to keep winning, not in any customer's inability to leave.